Dr Siefker-Radtke explores unmet needs in the treatment of patients with urothelial cancer and how novel immunotherapies can address some of the challenges with traditional chemotherapy.

Watch

EP. 3: EV+P Combination Strategy Changing Bladder Cancer Treatment Landscape

November 4th 2022

Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer.

Watch

EP. 4: SOGUG-AUREA Study Overview

November 4th 2022

The SOGUG-AUREA study explored overall survival of atezolizumab plus split-dose cisplatin-gemcitabine in patients with locally advanced and metastatic urothelial cancer.

Watch

EP. 5: SOGUG-AUREA Trial Results Impacting Next-Steps for Bladder Cancer Treatment

November 11th 2022

Dr Siefker-Radtke shares takeaways from the SOGUG-AUREA study and its influence on treatment for patients with urothelial cancer.

Watch

EP. 6: Exploring the Role of Disitamab Vedotin in the Treatment of Metastatic Urothelial Cancer

November 11th 2022

Disitamab vedotin is a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer.

Watch

EP. 7: Penpulimab Plus Anlotinib Evaluated for Previously Treated Urothelial Cancers

November 11th 2022

Dr Siefker-Radtke provides her closing thoughts on her takeaways from ESMO 2022, including a study focusing on penpulimab plus anlotinib.